[Clinical significance of heterozygosity loss at Mfn2 gene in hepatocellular carcinoma]

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010 Sep;39(5):506-10. doi: 10.3785/j.issn.1008-9292.2010.05.011.
[Article in Chinese]

Abstract

Objective: To investigate the loss of heterozygosity (LOH) at mitofusin-2 (Mfn2) gene in hepatocellular carcinoma (HCC) and its clinicopathological significance.

Methods: Four high polymorphic microsatellite markers flanking Mfn2 were selected for LOH analysis in 29 cases of HCC.

Result: The frequencies of LOH on D1S2667, D1S2740, D1S434 and D1S228 were 21%, 23%, 21% and 22%, respectively. LOH at Mfn2 was closely correlated with tumor size, age, capsule, differentiation and t HBV infection (P<0.05), not with gender, thrombosis, cirrhosis and serum AFP levels (P>0.05).

Conclusion: LOH at Mfn2 gene in HCC is associated with the clinicopathological features of patients.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Hepatocellular / genetics*
  • Female
  • GTP Phosphohydrolases
  • Humans
  • Liver Neoplasms / genetics*
  • Loss of Heterozygosity*
  • Male
  • Membrane Proteins / genetics*
  • Middle Aged
  • Mitochondrial Proteins / genetics*

Substances

  • Membrane Proteins
  • Mitochondrial Proteins
  • GTP Phosphohydrolases
  • MFN2 protein, human